PXD060526

PXD060526 is an original dataset announced via ProteomeXchange.

Title	Antidiabetic PPARγ Antidiabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer cellsonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer cells
Description	Background: Prostate cancer (PCa) and Type 2 diabetes (T2D) are two major health risks that often occur concurrently in men. Studies predict that diabetic PCa patients have a reduced risk of PCa progression, while other studies show contradicting data. This impedes unraveling the connection between PCa with T2D. Besides other drugs, Peroxisome Proliferator-Activated Receptor (PPAR) agonists have been applied as T2D medication in patients. In publicly available patient datasets high PPARγ expression correlated with advanced PCa and worse survival outcomes. Aim: We investigated the effect of PPAR agonists Bezafibrate (PPARα), Tesaglitazar (PPARα/γ), and Pioglitazone (PPARγ) on PCa tumorigenesis using primary PCa 22RV1 and metastatic PC3 cells. To get an unbiased view on the proteome repertoire of primary and metastatic PCa cells, we analysed their proteome at basal culture conditions and following treatment with PPAR agonists Bezafibrate, Tesaglitazar, and Pioglitazone. As compared to vitality assays, we chose a relatively short (24h) treatment period, assuming that early proteome alterations might provide mechanistic insight to explain the effect of PPAR agonists on vitality and proliferation.
HostingRepository	PRIDE
AnnounceDate	2025-08-11
AnnouncementXML	Submission_2025-08-11_08:17:31.014.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Ulrike Resch
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	methionine oxidation with neutral loss of 64 Da; iodoacetamide derivatized residue
Instrument	Exactive Plus

Revision	Datetime	Status	ChangeLog Entry
0	2025-02-05 14:12:03	ID requested
⏵ 1	2025-08-11 08:17:32	announced

10.1186/s12943-025-02320-y;

Atas E, Berchtold K, Schlederer M, Prodinger S, Sternberg F, Pucci P, Steel C, Matthews JD, James ER, Philippe C, Trachtov, á K, Moazzami AA, Artamonova N, Melchior F, Redmer T, Timelthaler G, Pohl EE, Turner SD, Heidegger I, Krueger M, Resch U, Kenner L, agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer. Mol Cancer, 24(1):134(2025) [pubmed]

submitter keyword: Prostate cancer cells

PPAR agonists

proteome and metabolic reprogramming

Ulrike Resch
contact affiliation	Medical University of Vienna Center of Physiology and Pharmacology Department of Vascular Biology and Thrombosis Research Schwarzspanierstraße 17/I A- 1090 Vienna, Austria
contact email	ulrike.resch@meduniwien.ac.at
lab head
Ulrike Resch
contact affiliation	Medical University of Vienna, Deptartment of Vascular Biology and Thrombosis Research
contact email	ulrike.resch@meduniwien.ac.at
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/08/PXD060526

PRIDE project URI

• PRIDE
  1. PXD060526
     1. Label: PRIDE project
     2. Name: Antidiabetic PPARγ Antidiabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer cellsonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer cells